BUSINESS

Daiichi Sankyo to Commercialize Amgen’s 9 Investigational Biosimilars Including Adalimumab in Japan

July 15, 2016

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Daiichi Sankyo announced on July 14 that the company has entered into an exclusive deal with Amgen for commercializing the US company’s nine investigational biosimilars in Japan. Of these nine products, three products, biosimilars of adalimumab, bevacizumab, and trastuzumab, are…

To read the full story

Daiichi Sankyo to Transfer Avastin Biosimilar to Amgen in Japan
January 8, 2025
Daiichi Sankyo’s Herceptin Biosimilar Might Hit Market as Early as November, Breast Cancer Use Also Eyed
July 23, 2018

BUSINESS

FDA Rejects Regenxbio/Nippon Shinyaku’s MPS II Gene Therapy
February 12, 2026
Celltrion to Launch Japan’s First Actemra Biosimilar in Late April
February 12, 2026
Takeda’s Narcolepsy Drug Accepted for US FDA Review
February 12, 2026
Kyowa Kirin Targets 20-Plus New Pipeline Assets by Early 2030s
February 10, 2026
Kyowa Kirin’s FY2025 Core Operating Profit Hits Record High as Costs Fall
February 10, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…